



COMPETITIVE TECHNOLOGIES FORMS ALLIANCE WITH NCS PHARMACEUTICALS

Fairfield, CT – (September 6, 2007) – Competitive Technologies, Inc. (AMEX: CTT) announced today that they have formed a strategic alliance with NCS Pharmaceuticals LLC. The Somerset, NJ-based NCS will work with CTT in the therapeutic drug, medical diagnostic, analytical testing and nutraceutical markets. NCS will evaluate the pharmacokinetic and pharmacodynamic properties of selected therapeutic analogues of current or newly acquired technologies in CTT's portfolio.

"The alliance with NCS brings CTT an effective, experienced partner and broadens our ability to evaluate and commercialize therapeutic and nutraceutical technologies," said Aris D. Despo, CTT's Sr. VP, Business Development. "NCS's excellent cGMP/cGLP (current Good Manufacturing Practices, and current Good Laboratory Practices) compliance and validation program will allow CTT to streamline the fulfillment of FDA requirements to commercialize our technologies. NCS will work with CTT to determine the best lead candidates of peptide analogues for antimicrobial and wound healing therapeutics that we are evaluating for licensing and commercialization. NCS will immediately contribute to projects requiring analysis and development of assays specific to nutraceutical applications that solve unmet needs in the marketplace."

CTT's extensive portfolio of commercially viable technologies includes several innovative life science technologies that NCS will work with. These include the glycemic reduction nutraceutical and the green tea polyphenol compounds, as well as bone biomaterial, cholesterol trapping and regeneration, and a wound sealant.

"As a leader in product and analytical support, NCS is pleased to join CTT in this alliance," said Dr. Nikhil Saha, NCS's President and CEO. "It will allow us to create an important relationship with CTT, who will act as the sourcing agent for the many technologies we expect to jointly commercialize. NCS looks forward to collaborating with CTT on projects and advancing the technology commercialization process."

Mr. Despo continued, "The NCS agreement allows us to broaden our FDA-compliance capabilities as we expand our nutraceutical opportunities. Also, we are bringing to market an important compliance service and materials testing, especially in response to the uncertainty in the quality of foreign materials, that meets CTT's strategy of fulfilling consumer needs, and serves our clients, CTT and our shareholders by generating recurring revenue and increasing shareholder value."

About NCS Pharmaceuticals LLC

NCS Pharmaceuticals is a Contract Research Organization (CRO) providing research and development, product support, analytical support, and method development and validation. The NCS analytical testing laboratory offers services to pharmaceutical, medical device, food, dietary supplement, cosmetics, chemical, environmental, and allied industries. Visit NCS's website at www.ncspharma.com

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net

Statements about our future expectations are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words "may," "will," "should," "anticipate," "believe," "appear," "intend," "plan," "expect," "estimate," "approximate," and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in Item 1A under the caption "Risk Factors," in our most recent Annual Report on Form 10-K for the year ended July 31, 2006, filed with the SEC on October 30, 2006, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

Direct inquiries to: Johnnie D. Johnson, IR Services, LLC
Tel: 860 434 2465
E-mail: jdjohnson@corpirservices.com